Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
Ancora Biotech has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Ancora Biotech's investors include Lightspeed Venture Partners, SR One.
Ancora Biotech is headquartered in Palo Alto, United States.
Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
Ancora Biotech is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ancora Biotech — Funding & Investors." VCBacked, June 9, 2022, https://www.vcbacked.co/company/ancora-biotech. Accessed August 14, 2026.
VCBacked. (2022). Ancora Biotech — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/ancora-biotech
{{cite web |title=Ancora Biotech — Funding & Investors |url=https://www.vcbacked.co/company/ancora-biotech |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated